Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
about
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancerChemotherapy and radiotherapy for inoperable advanced pancreatic cancerRecent progress in pancreatic cancerPancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancerPhase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveSystemic treatment for inoperable pancreatic adenocarcinoma: review and updateFOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancerMetastatic pancreatic cancer: Is there a light at the end of the tunnel?Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancerEnzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinomaFixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancerRandomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.Evolution of systemic therapy for advanced pancreatic cancer.High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignanciesRecent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.Noninvasive characterization of pancreatic tumor mouse models using magnetic resonance imagingDiagnosis and management of pancreatic cancer.Gemcitabine and Vinorelbine (GemVin) RegimenKRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma.Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.Current and emerging therapies for the treatment of pancreatic cancer.Pancreatic adenocarcinomaRandomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group StudyPharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.
P2860
Q24240739-EC22A9CE-ECFB-4CAE-9DE7-208E79AE8C60Q24245085-94936D57-2794-46EC-935E-EF3C4B326E65Q24626346-7A5F2A41-7372-401D-88B8-3228DB9D5F37Q24631880-D19B8847-64B2-49B6-AD35-4A7E19CEEFEEQ24814067-49462E70-E9E8-4AF3-A602-B9A4F90EC07BQ26752368-C523A482-9295-4E8E-BA71-9F5647DE4B6DQ26830913-7607E177-1154-48B2-80D1-82FF6F8977C7Q28075540-998C9C8A-8C65-4D58-937D-8A2DAD308500Q28082919-E9520192-E787-4F6C-A829-0685C258DD06Q29547558-F9E8AD66-51E6-4E9D-A114-9AEF0123A884Q29616287-63C5F242-C257-4094-8835-1134F7D5D4DDQ30439459-AF852492-30DD-42AC-8452-8A9360B89C4DQ33265964-3B6E2356-FFE1-4718-8715-BEE1FD3B7F3BQ33360849-4A3EAEA1-D758-44DB-AE77-2DE5B13977A6Q33371000-9B2B2917-AF96-4410-A192-78E5F3A9A865Q33371225-C4EE755F-69AC-45AC-B6F4-BBE80D2123E7Q33385281-4ECE445D-AA7E-4E61-A501-C6C694F0BCB0Q33388412-E61164D2-AFB9-41FC-B5A8-3DF87305B402Q33389524-4CB393B2-DDA3-4732-BEA7-869D0B768B4EQ33397403-3370ED6F-7483-4681-9B2C-85C1E2D64EC0Q33400984-1A63E5F2-0733-4F67-B7BD-C41409AA6BE8Q33401071-91EDCD5C-0E6F-4581-AD6F-EC6E63F742C7Q33402401-B666925D-5289-41E1-B3C8-F7A507AB58DBQ33402598-828C210A-E734-4605-BAB5-F530E220A180Q33407276-2A3F1AF6-39C6-4B64-AB1F-7F5B5E3E81A5Q33417698-652F6E85-F744-4B3A-9FAC-E22D34F07400Q33418849-9BF254F2-BA0B-4FEA-ACD0-0770FB0054BEQ33557413-EACA3051-8B72-416D-BE5D-6A0749825288Q33566475-CA37514D-EB64-4FD0-BA85-FBFA1CC1A3E0Q33632330-E716A2E9-03BA-4E01-9B51-81C0437F0AA4Q33679670-CC319024-D5F3-47A4-9F1B-79F476DCA990Q33759924-5D913C03-7093-4588-89D1-BD592D1A35BFQ33774738-89E64BD1-2503-4DF0-8F4F-55C54B1A272FQ33858490-69B470CC-8E15-4A34-9D91-8EAA0FF32700Q33887648-3E072236-92BC-42EF-80A3-9AC955EF3D65Q34009357-3C9DD902-2803-4DE9-9FEC-9A73B8F2F6C4Q34129346-3CD5A092-9ADB-4035-AA6D-516D762C1660Q34140498-1A798397-DD0A-4CA3-806A-DC0B0B2BD261Q34257664-08CED610-FEF5-4BDB-839E-ABFEA89DE6ACQ34425234-1D573B95-B597-4AEC-ACCA-74BE34537435
P2860
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Randomized phase II comparison ...... ith pancreatic adenocarcinoma.
@en
Randomized phase II comparison ...... ith pancreatic adenocarcinoma.
@nl
type
label
Randomized phase II comparison ...... ith pancreatic adenocarcinoma.
@en
Randomized phase II comparison ...... ith pancreatic adenocarcinoma.
@nl
prefLabel
Randomized phase II comparison ...... ith pancreatic adenocarcinoma.
@en
Randomized phase II comparison ...... ith pancreatic adenocarcinoma.
@nl
P2093
P356
P1476
Randomized phase II comparison ...... ith pancreatic adenocarcinoma.
@en
P2093
Howard Hochster
James Abbruzzese
Renato Lenzi
Veronique Ruiz Van Haperen
William Plunkett
P304
P356
10.1200/JCO.2003.09.140
P407
P577
2003-07-28T00:00:00Z